Notice Number: NOT-CA-14-037

Key Dates
Release Date: March 24, 2014
Estimated Publication Date of Announcement: Spring 2014
First Estimated Application Due Date: Fall 2014
Earliest Estimated Award Date: Summer 2015
Earliest Estimated Start Date: Summer 2015

Related Announcements
NOT-CA-14-033
NOT-CA-14-035

Issued by
National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) supports the development of translational nanotechnologies with applications in the diagnosis and therapy of cancer through its Alliance for Nanotechnology in Cancer program. Cancer nanotechnology is widely viewed as a promising and highly innovative field, with the potential for transformative scientific advancements and practical applications relevant to cancer.

The forthcoming Funding Opportunity Announcement (FOA) introduced by this Notice, to be issued by the NCI, will solicit U01 (Research Project-Cooperative Agreements) applications. This initiative is open to all qualified applicants regardless of whether or not they participated in the previous cycle of the Alliance for Nanotechnology in Cancer program.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications.  

This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

The forthcoming FOA announced by this Notice will be open to all qualified applicants with the appropriate expertise to establish, evolve, and maintain a cancer nanotechnology research program.

The proposed research projects are expected to address major questions in cancer biology and cancer interventions through the use of innovative nanotechnology. These projects will be expected to develop further understanding of nanomaterial interactions with biological systems and mechanisms of their in vivo delivery. To advance such new nanotechnology discoveries, the proposed platform projects should take advantage of the collaborative environment of the Alliance network.  

Further details will be included in the forthcoming FOA.

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Dr. Piotr Grodzinski
National Cancer Institute (NCI)
Telephone: 301-454-8983
Email: [email protected]